Asymmetric Dimethylarginine and Homocysteine Levels in Dialysis Patients

Basit Öğe Kaydı
dc.contributor.authorErdem, S. Sami
dc.contributor.authorYerlikaya, F. Humeyra
dc.contributor.authorTonbul, Zeki
dc.contributor.authorTurkmen, Kultigin
dc.contributor.authorErdur, F. Mehmet
dc.contributor.authorTaner, Alpaslan
dc.contributor.authorCicekler, Humeyra
dc.date.accessioned2024-02-23T14:34:25Z
dc.date.available2024-02-23T14:34:25Z
dc.date.issued2013
dc.departmentNEÜen_US
dc.description.abstractCardiovascular diseases and endothelial disfunction are major causes of mortality in patients with end stage renal disease (ESRD). Treatment strategies like continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) have different effects on different parameters. Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide (NO) synthase inhibitor and it has been reported to be a novel marker for the progression of chronic kidney disease (CKD). Homocysteine is believed to cause atherogenesis and thrombogenesis via endothelial damage, vascular smooth muscle proliferation and coagulation abnormalities. In previous studies, conflicting findings have been reported about the effect of HD and CAPD on oxidant and antioxidant systems. In this study, we aimed to investigate ADMA, homocysteine and C-reactive protein (CRP) levels in patients with ESRD having HD and CAPD treatment and healthy individuals. This study was performed on 44 (23M, 21F) CAPD patients, 26 (13M, 13F) HD patients and 29 (15M, 14F) age and sex matched healthy control subjects. The lipid profile, ADMA, homocysteine, arginine and CRP levels were measured. Serum ADMA, homocysteine and CRP levels of the ESRD patients were significantly higher, whereas serum arginine levels were significantly lower in both HD and CAPD patients compared to control subjects. No differences were found between serum ADMA, homocysteine and CRP levels of the CAPD and HD patients. Our results suggest that ADMA, homocysteine and CRP levels were increased in HD and CAPD patients compared to the control subjects. These findings suggest that ESRD patients are prone to inflammation, oxidative stress and endothelial dysfunction. We conclude that endothelial dysfunction, inflammation and oxidative stress are increased in dialysis patients and ADMA concentrations are not affected by the modality of dialysis treatment.en_US
dc.identifier.doi10.29333/ejgm/82285
dc.identifier.endpage95en_US
dc.identifier.issn1304-3889
dc.identifier.issn1304-3897
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-84880340779en_US
dc.identifier.startpage90en_US
dc.identifier.urihttps://doi.org/10.29333/ejgm/82285
dc.identifier.urihttps://hdl.handle.net/20.500.12452/15604
dc.identifier.volume10en_US
dc.identifier.wosWOS:000421930200005en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherModestum Ltden_US
dc.relation.ispartofEuropean Journal Of General Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAsymmetric Dimethylarginineen_US
dc.subjectHomocysteineen_US
dc.subjectHemodialysisen_US
dc.titleAsymmetric Dimethylarginine and Homocysteine Levels in Dialysis Patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu